Sanofi and Regeneron Pharmaceuticals Inc.'s novel therapy Dupixent (dupilumab) has hit both primary endpoints in a Phase III trial in asthma, showing a greater benefit in those most allergic form of the disease and setting the stage for a US FDA filing to expand its indications by the end of the year.
The product – which was approved in March by the FDA for the treatment of moderate-to-severe atopic dermatitis in adult...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?